Compare AstraZeneca plc (AZN) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Star Bulk Carriers Corp — how do they compare? AstraZeneca plc trades at $157.87 (market cap $248.14B), while Star Bulk Carriers Corp trades at $27.89 (market cap $3.09B). The key difference: AstraZeneca plc is far larger — about 80.3× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays the higher dividend (6.79%). Which is the better fit depends on your goals.
| AZN | SBLK | |
|---|---|---|
Market Cap | $248.14B | $3.09B |
Sector | Health | Industrials |
52-Week High | $209.48 | $29.15 |
52-Week Low | $147.06 | $16.79 |
Enterprise Value | $275.41B | $3.77B |
Dividend Yield | 2.01% | 6.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Star Bulk Carriers (SBLK) trades at $27.80, down 2.18% on the day, with a bullish technical signal from moving averages and strong quarterly earnings beats. The company reported robust Q2 2026 results with net income of $144.9 million and declared a $0.90 dividend, reflecting operational strength. Revenue grew to $1.2 billion in 2026, with net profit margin expanding to 23.86%, while valuation ratios like P/E of 10.85 and EV/EBITDA of 7.46 suggest reasonable pricing. Recent news highlights termination of a vessel agreement with Diana Shipping, but operational updates remain positive.
SBLK presents a favorable outlook with earnings momentum, high dividend yield, and analyst buy consensus, though risks include dry bulk rate volatility and competitive pressures. The stock's fundamental health supports potential upside, but investors should weigh cyclical industry exposure against strong cash flow generation and balance sheet flexibility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
